Mepolizumab, an IL-5 antagonist, is being evaluated for its efficacy in severe eosinophilic asthma, a market segment with significant unmet needs. The study aims to identify predictive and prognostic biomarkers for treatment response, which could enhance patient stratification and improve therapeutic outcomes. Given the increasing prevalence of asthma and the growing demand for targeted biologics, successful outcomes could position mepolizumab favorably against competitors like dupilumab and other emerging therapies. The collaboration with GlaxoSmithKline indicates strong industry backing, potentially facilitating broader market access and commercialization strategies.